VJHemOnc is committed to improving our service to you

ISA 2020 | Optimism for amyloidosis therapy

VJHemOnc is committed to improving our service to you

Joel Buxbaum

Joel Buxbaum, MD, Scripps Research, La Jolla, CA, talks on improvements in amyloidosis management in recent years, commenting on the progression of options and outcomes in AL amyloidosis. Prof. Buxbaum goes on to discuss the issue of organ responses, specifically cardiac responses and recent advances such as the use of patisiran for the treatment of polyneuropathy in patients with hereditary transthyretin-mediated amyloidosis. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter